Randomized trial · people
Tesamorelin cut visceral and liver fat over 6 months in HIV patients
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In people with HIV, 6 months of tesamorelin lowered belly fat and modestly lowered liver fat, with an early rise in fasting glucose that was no longer significant at 6 months.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 50
- Published
- 2014
- Journal
- JAMA
What they tested
The team wanted to know whether daily tesamorelin lowers both visceral fat (fat inside the belly) and liver fat in people with HIV who carry extra abdominal fat.
How the study was done
A double-blind, randomized, placebo-controlled trial at one Boston hospital in 50 men and women with HIV on antiretroviral treatment and abdominal fat buildup. They got tesamorelin 2 mg (28 people) or placebo, a dummy shot (22 people), as a daily injection under the skin for 6 months.

What they found
Visceral fat fell by an average of 34 cm2 on tesamorelin and rose by 8 cm2 on placebo, a significant treatment effect of -42 cm2. Liver fat, measured as a lipid to water percentage, dropped by a median of 2.0% on tesamorelin and rose by 0.9% on placebo, a significant net effect of -2.9%. Fasting glucose went up more on tesamorelin at 2 weeks (9 mg/dL vs 2 mg/dL), a significant difference. By 6 months, the differences in fasting glucose and 2-hour glucose between groups were not significant.
What it doesn’t show
This was a small, preliminary trial at a single center that lasted 6 months, and it only included people with HIV and extra abdominal fat. It does not show whether the fat changes matter for health or what happens over the long term.
The paper
Stanley et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014.
The compound
More studies on Tesamorelin
- Tesamorelin: visceral fat down 27.71 cm² in HIV lipodystrophyMeta-analysis · people · 2026
- Tesamorelin shifted liver gene activity in HIV-related fatty liverRandomized trial · people · 2020
- Tesamorelin: denser, larger trunk muscles at 26 weeks in HIVRandomized trial · people · 2019
- Tesamorelin: no change in glucose control in type 2 diabetesRandomized trial · people · 2017
- Tesamorelin had little effect on simvastatin and ritonavir levelsRandomized trial · people · 2013
- Tesamorelin cut visceral fat 15.4% vs placebo in HIV at 26 weeksRandomized trial · people · 2010
- Every study on Tesamorelin
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.